医学
痛风
重症监护医学
指南
非布索坦
痹症科
临床试验
物理疗法
临床实习
高尿酸血症
内科学
尿酸
病理
作者
Lisa K. Stamp,Nicola Dalbeth
标识
DOI:10.1016/j.semarthrit.2023.152358
摘要
The 'treat-to target serum urate strategy' when using urate-lowering therapy has been recommended by most specialist rheumatology societies for many years. An alternative "treat-to-avoid-symptoms" in gout has been suggested, albeit without a clear definition of what this means and how it might be implemented in clinical trials or clinical practice. This has hampered efforts to design clinical trials that compare the "treat-to-target [urate]" and "treat-to-avoid-symptoms" strategies in the long-term management of gout. In this review we consider the rationale for the treat-to-target urate strategy when using urate-lowering therapy, potential definitions of a "treat-to-avoid-symptoms" strategy, or perhaps what is not "treat-to-avoid-symptoms", and approaches that might address this uncertainty.
科研通智能强力驱动
Strongly Powered by AbleSci AI